Mirapexin prolonged release formulation launched

A once daily formulation of pramipexole (Mirapexin Prolonged Release) has been launched for the treatment of idiopathic Parkinson's disease.

The new preparation is available in five strengths: 0.26mg, 0.52mg, 1.05mg, 2.1mg and 3.15mg.
Treatment with Mirapexin Prolonged Release should be initiated at 0.26mg daily, increasing to a maximum of 3.15mg per day as necessary.

View Mirapexin drug record

Further information: Boehringer

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Statin prescribing 'commonly breaching NICE guidance'

Statin prescribing 'commonly breaching NICE guidance'

Prescribing of suboptimal statin regimens is 'extremely...

New contraindication for co-cyprindiol

New contraindication for co-cyprindiol

Cyproterone-containing medicines are now contraindicated...

GPs demand clarity on flu vaccination plans for 2020/21

GPs demand clarity on flu vaccination plans for 2020/21

GPs say they are struggling to plan flu vaccine orders...